COPD & Its Management

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease characterised by persistent respiratory symptoms and airflow limitation that is not fully reversible, due to airway and/or alveolar abnormalities from significant exposure to noxious particles or gases. It is a perennial NEET PG favourite — expect questions on spirometry cut-offs, GOLD ABE grouping, phenotypes, and exacerbation/LTOT criteria.

Definition & Classification

COPD is defined physiologically by a post-bronchodilator FEV1/FVC < 0.70, confirming non-reversible airflow obstruction. It is an umbrella term encompassing:

• Chronic bronchitis — a clinical diagnosis: productive cough for ≥3 months in ≥2 consecutive years (after excluding other causes).
• Emphysema — a pathological/anatomical diagnosis: permanent dilatation of airspaces distal to the terminal bronchiole with destruction of alveolar walls, without obvious fibrosis.
• Small airway disease (obstructive bronchiolitis) — increasingly recognised as the earliest lesion.

High-yield: COPD diagnosis requires spirometry showing post-bronchodilator FEV1/FVC < 0.70. A clinical picture alone is never sufficient for the exam answer.

GOLD spirometric grading (severity of airflow limitation)

Applied only after FEV1/FVC < 0.70 is established, using post-bronchodilator FEV1 % predicted:

GOLD grade	Severity	FEV1 (% predicted)
GOLD 1	Mild	≥ 80%
GOLD 2	Moderate	50–79%
GOLD 3	Severe	30–49%
GOLD 4	Very severe	< 30%

GOLD "ABE" assessment (drives initial therapy)

The 2023/2024 GOLD update collapsed the old C and D groups into a single "E" (Exacerbation) group. Grouping uses symptom burden (mMRC or CAT) and exacerbation history:

Group	Exacerbations (last yr)	Symptoms	Notes
A	0–1 (no hospitalisation)	Low (mMRC 0–1 / CAT < 10)	Less symptoms, low risk
B	0–1 (no hospitalisation)	High (mMRC ≥ 2 / CAT ≥ 10)	More symptoms, low risk
E	≥ 2 moderate OR ≥ 1 needing hospitalisation	Any	High exacerbation risk

High-yield: The 2023 GOLD revision merged C+D into E. If a stem describes ≥2 exacerbations or ≥1 hospitalisation, the answer is Group E, regardless of symptom score.

Etiology & Risk Factors

• Cigarette smoking — the single most important cause worldwide (dose-dependent, pack-years).
• Biomass fuel exposure / indoor air pollution — major cause in Indian women (chulha smoke) and non-smokers.
• Occupational dusts (silica, cadmium), outdoor pollution.
• Alpha-1 antitrypsin (A1AT) deficiency — the classic genetic cause; suspect in young (<45 yr), non-smoker, basal/panacinar emphysema, often with liver disease. PiZZ genotype is most severe.
• Recurrent childhood infections, low birth weight, poorly controlled asthma.

Pathophysiology

Noxious exposure → chronic inflammation (neutrophils, CD8+ T-lymphocytes, macrophages) → protease–antiprotease imbalance and oxidative stress → two parallel processes:

1. Small airway disease → goblet cell hyperplasia, mucus hypersecretion, peribronchiolar fibrosis → increased airway resistance.
2. Parenchymal destruction (emphysema) → loss of elastic recoil and alveolar attachments → dynamic airway collapse on expiration → air trapping and hyperinflation.

The cascade: Air trapping → ↑ residual volume & FRC → hyperinflation → flattened diaphragm → ↑ work of breathing → dynamic hyperinflation on exertion → exertional dyspnoea. Loss of capillary bed + hypoxic pulmonary vasoconstriction → pulmonary hypertension → cor pulmonale.

High-yield: Hallmark of emphysema is decreased DLCO (loss of alveolar–capillary surface). In asthma and chronic bronchitis without emphysema, DLCO is normal or raised. DLCO is a favourite discriminator.

Emphysema subtypes

Type	Region of acinus	Association
Centriacinar (centrilobular)	Proximal/respiratory bronchiole, upper lobes	Smoking (commonest)
Panacinar	Entire acinus, lower lobes	A1AT deficiency
Paraseptal (distal acinar)	Distal acinus, subpleural	Spontaneous pneumothorax in young adults
Irregular	Around scars	Healed TB/granulomas

Clinical Features — The Two Classic Phenotypes

This eponymous comparison is among the most repeated COPD MCQs.

Feature	Pink Puffer (Type A)	Blue Bloater (Type B)
Underlying lesion	Emphysema predominant	Chronic bronchitis predominant
Dyspnoea	Severe, early	Mild, late
Cough/sputum	Scanty	Copious, chronic productive
Body habitus	Thin, cachectic	Overweight
Chest	Barrel chest, ↑ AP diameter	—
PaO2	Mildly reduced	Markedly reduced (cyanosis)
PaCO2	Normal/low	Elevated (CO2 retainer)
Cor pulmonale	Late	Early & frequent
Polycythaemia	Uncommon	Common
DLCO	Markedly ↓	Relatively preserved

Mnemonic: Pink Puffer = Pink (well-oxygenated), Pursed-lip breathing, Puffing/dyspnoeic. Blue Bloater = Blue (cyanosed), Bloated (oedema/cor pulmonale), Bronchitis.

High-yield: Pursed-lip breathing creates auto-PEEP, splinting open collapsing airways and reducing dynamic hyperinflation — classically seen in the pink puffer.

Examination: prolonged expiration, wheeze, hyperresonant percussion, reduced breath sounds, loss of cardiac/hepatic dullness, use of accessory muscles, Hoover's sign (paradoxical indrawing of lower costal margins on inspiration due to flat diaphragm).

Diagnosis & Investigations

Investigation of choice for diagnosis: post-bronchodilator SPIROMETRY.

• Spirometry: ↓ FEV1, ↓↓ FEV1/FVC (< 0.70). Obstructive pattern; minimal reversibility (< 12% / 200 mL improvement post-bronchodilator distinguishes from asthma, though overlap exists).
• Lung volumes (body plethysmography): ↑ TLC, ↑ RV, ↑ FRC (hyperinflation/air trapping).
• DLCO: reduced in emphysema.
• Chest X-ray: hyperinflation — flattened diaphragm, >6 anterior / >10 posterior ribs, ↑ retrosternal air space (lateral film), narrow tubular ("teardrop") heart, bullae, attenuated peripheral vessels.
• HRCT chest: most sensitive for emphysema and bullae; mandatory before lung volume reduction/transplant work-up.
• ABG: in advanced disease — hypoxaemia ± compensated respiratory acidosis (↑PaCO2, ↑HCO3⁻, near-normal pH). NEET PG loves pairing COPD with ABG: expect chronic compensated type 2 respiratory failure.
• Serum A1AT level: in young/non-smoker/family history/basal emphysema.
• ECG: P pulmonale, RAD, RVH, RBBB (cor pulmonale).

High-yield: On CXR, flattening of the diaphragm is the single most reliable sign of hyperinflation. The "teardrop/tubular heart" reflects vertical heart from hyperinflated lungs.

Management of Stable COPD

Non-pharmacological (most important)

1. Smoking cessation — the only intervention proven to slow FEV1 decline and reduce mortality. → This is the single most effective measure.
2. Vaccination — influenza (annual), pneumococcal (PCV/PPSV), COVID-19, and pertussis where indicated.
3. Pulmonary rehabilitation — improves dyspnoea, exercise tolerance and quality of life (esp. Group B/E).
4. Nutrition, treatment of comorbidities.

High-yield: Only smoking cessation and long-term oxygen therapy (LTOT) in hypoxaemic patients are proven to improve survival/reduce mortality in COPD. Inhalers improve symptoms and reduce exacerbations but do not clearly reduce mortality.

Pharmacological — inhaler classes

Class	Examples	Mechanism
SABA	Salbutamol, terbutaline	Short-acting β2 agonist
SAMA	Ipratropium	Short-acting muscarinic antagonist
LABA	Salmeterol, formoterol, indacaterol	Long-acting β2 agonist
LAMA	Tiotropium, glycopyrronium, umeclidinium	Long-acting muscarinic antagonist
ICS	Budesonide, fluticasone	Inhaled corticosteroid (add-on only)

GOLD initial therapy by group (flow):

• Group A → a bronchodilator (SABA, or a LAMA/LABA).
• Group B → LABA + LAMA combination.
• Group E → LABA + LAMA; add ICS (→ LABA + LAMA + ICS, "triple therapy") if blood eosinophils ≥ 300 cells/µL or features of asthma overlap.

High-yield: Eosinophil count guides ICS use. ICS is favoured when eos ≥ 300/µL; generally avoided when eos < 100/µL (little benefit, ↑ pneumonia risk). LAMA is the preferred bronchodilator for reducing exacerbations.

• Roflumilast (PDE-4 inhibitor): for severe COPD with chronic bronchitis + frequent exacerbations.
• Azithromycin (prophylactic, esp. ex-smokers): reduces exacerbations.
• Theophylline: weak bronchodilator, narrow therapeutic index — now rarely first-line.
• ICS is never used as monotherapy in COPD (unlike asthma).

Long-Term Oxygen Therapy (LTOT)

Aim for ≥15 hours/day. Indications (resting, stable, on optimal therapy):

• PaO2 ≤ 55 mmHg (or SaO2 ≤ 88%), OR
• PaO2 56–59 mmHg (≤ 60) with evidence of: cor pulmonale / right heart failure, pulmonary hypertension, or polycythaemia (haematocrit > 55%).

High-yield: LTOT improves survival only in chronically hypoxaemic patients. Goal SaO2 ≥ 90% (PaO2 ≥ 60 mmHg). Beware over-oxygenation in CO2 retainers (target SpO2 88–92%).

Surgical / interventional

• Lung volume reduction surgery (LVRS) — best benefit in upper-lobe predominant emphysema with low exercise capacity.
• Endobronchial valves (bronchoscopic LVR), bullectomy, lung transplantation.

Management of Acute Exacerbation of COPD (AECOPD)

An exacerbation = acute worsening of respiratory symptoms needing additional therapy. Cardinal Anthonisen criteria: ↑ dyspnoea, ↑ sputum volume, ↑ sputum purulence.

Commonest trigger: respiratory infection (viral > bacterial; H. influenzae, S. pneumoniae, M. catarrhalis).

Stepwise approach:

1. Controlled oxygen → target SpO2 88–92% (venturi mask preferred). Avoid high-flow uncontrolled O2 → risk of CO2 narcosis.
2. Bronchodilators → nebulised SABA + SAMA (salbutamol + ipratropium).
3. Systemic corticosteroids → oral prednisolone 40 mg × 5 days (REDUCE trial — short course non-inferior).
4. Antibiotics → when ≥2 Anthonisen criteria (esp. purulent sputum) or ventilatory support needed; typically amoxicillin-clavulanate/macrolide/doxycycline.
5. NIV (BiPAP) → for respiratory failure (see below).

High-yield: NIV (BiPAP) is the intervention of choice for AECOPD with acute hypercapnic respiratory failure: pH 7.25–7.35 with PaCO2 > 45 mmHg, persisting despite medical therapy. It reduces intubation rate, mortality and length of stay.

NIV indications: respiratory acidosis (pH ≤ 7.35, PaCO2 ≥ 45), severe dyspnoea with accessory muscle use/paradox. NIV contraindications / proceed to intubation: respiratory arrest, ↓ consciousness/inability to protect airway, haemodynamic instability, copious secretions, pH < 7.25 not responding to NIV.

Mnemonic for AECOPD management — "ABC-NO": Antibiotics, Bronchodilators, Corticosteroids, NIV, Oxygen (controlled).

Complications

• Cor pulmonale and right heart failure (commonest serious complication).
• Secondary polycythaemia (chronic hypoxaemia → ↑ erythropoietin).
• Pneumothorax (ruptured bulla).
• Type 2 respiratory failure (hypercapnic).
• Recurrent infections, pulmonary hypertension.
• Increased lung cancer risk, cachexia, osteoporosis, depression, cardiovascular disease.

Key Differentials

Condition	Distinguishing features
Asthma	Onset <40 yr, atopy/allergy, **reversible** obstruction (>12% & 200 mL), diurnal variation, eosinophilic, DLCO normal/↑
Bronchiectasis	Copious purulent sputum, haemoptysis, tram-track/signet-ring on HRCT, clubbing
Congestive cardiac failure	Orthopnoea, PND, bibasal crepts, cardiomegaly, raised BNP, restrictive pattern
Tuberculosis	Constitutional symptoms, upper-lobe infiltrates/cavities, sputum AFB/CBNAAT
Obliterative bronchiolitis	Younger, non-smoker, post-transplant/RA, HRCT mosaic attenuation

High-yield: Reversibility on spirometry is the classic asthma vs COPD discriminator, but ACO (asthma-COPD overlap) exists. A normal/raised DLCO with reversible obstruction favours asthma; reduced DLCO favours emphysema.

Recently asked / exam angle

• Spirometry cut-off: "Diagnosis of COPD requires FEV1/FVC < ?" → 0.70 (post-bronchodilator).
• GOLD ABE grouping: stems give exacerbation number + CAT/mMRC → identify A/B/E and pick initial inhaler (Group E → LABA+LAMA ± ICS).
• Eosinophil-guided ICS: add ICS if eos ≥ 300/µL.
• Phenotype matching: pink puffer vs blue bloater table; DLCO interpretation.
• A1AT deficiency: young non-smoker with basal panacinar emphysema + liver disease.
• LTOT indications: PaO2 ≤ 55 (or ≤ 59 with cor pulmonale/Hct >55%).
• NIV in AECOPD: pH 7.25–7.35 with hypercapnia → BiPAP.
• ABG integration: chronic compensated respiratory acidosis (type 2 failure); identify CO2 narcosis with uncontrolled O2.
• Drugs that improve survival: smoking cessation + LTOT (NOT inhalers).
• Emphysema subtype–region mapping: centriacinar/upper = smoking; panacinar/lower = A1AT.
• Roflumilast = PDE-4 inhibitor for chronic bronchitis phenotype with frequent exacerbations.

Rapid revision

1. COPD = post-bronchodilator FEV1/FVC < 0.70; spirometry is the investigation of choice.
2. GOLD grades 1–4 by FEV1 % predicted (≥80 / 50–79 / 30–49 / <30).
3. 2023 GOLD groups = A, B, E (C and D merged into E).
4. Smoking is the commonest cause; biomass smoke key in Indian women; A1AT deficiency in young non-smokers.
5. Centriacinar emphysema = upper lobes/smoking; panacinar = lower lobes/A1AT.
6. DLCO is reduced in emphysema — major discriminator from asthma.
7. Pink puffer = emphysema, thin, normocapnic; blue bloater = bronchitis, CO2 retainer, early cor pulmonale.
8. CXR hyperinflation = flat diaphragm, >6 anterior ribs, ↑ retrosternal space, tubular heart.
9. Hoover's sign and pursed-lip breathing (auto-PEEP) are classic emphysema signs.
10. Group E therapy = LABA + LAMA; add ICS if eosinophils ≥ 300/µL; never ICS monotherapy.
11. LTOT indicated at PaO2 ≤ 55 mmHg (or ≤ 59 with cor pulmonale/Hct > 55%); only smoking cessation + LTOT improve survival.
12. AECOPD: controlled O2 (SpO2 88–92%), nebulised SABA+SAMA, prednisolone 40 mg × 5 days, antibiotics if purulent; BiPAP for hypercapnic failure (pH 7.25–7.35).